UCB has been granted a patent for a drug combination that aims to reduce seizures in patients. The method involves administering fenfluramine, which produces a metabolite with adverse side effects, along with stiripentol, a CYP inhibitor that reduces the formation of the metabolite, making the first drug safer and increasing its effectiveness. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
A method of reducing seizures using fenfluramine and stiripentol
A recently granted patent (Publication Number: US11759440B2) describes a method for reducing or ameliorating seizures in patients diagnosed with refractory epilepsy, specifically Dravet syndrome, Lennox-Gastaut syndrome, Doose syndrome, and West syndrome. The method involves administering fenfluramine and stiripentol to the patient. Fenfluramine is a medication that has been shown to reduce seizures, while stiripentol is used to modulate down the formation of norfenfluramine, resulting in higher levels of fenfluramine.
The patent also includes the option of co-administering a co-therapeutic agent along with fenfluramine and stiripentol. The co-therapeutic agent can be selected from a wide range of medications commonly used to treat epilepsy, such as acetazolamide, barbexaclone, cannabidiol, clonazepam, diazepam, gabapentin, phenytoin, topiramate, and many others.
Furthermore, the patent describes the use of liquid formulations of fenfluramine and stiripentol for administration. The recommended dosage of fenfluramine is in the range of 0.2 mg/kg/day to 0.8 mg/kg/day, while stiripentol is administered in a dosage of about 20 mg/kg/day to about 50 mg/kg/day. The patent also suggests that the dosage of fenfluramine can be reduced by 30% or 40% when co-administered with stiripentol, depending on the specific condition being treated.
Overall, this patent provides a method for reducing seizures in patients with refractory epilepsy, particularly those diagnosed with Dravet syndrome. By combining the use of fenfluramine and stiripentol, the formation of norfenfluramine is modulated down, leading to higher levels of fenfluramine. The addition of co-therapeutic agents and the use of liquid formulations further enhance the effectiveness and ease of administration of the treatment.
To know more about GlobalData’s detailed insights on UCB, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
